

**Disclosure Purpose:** 21-19270

## Summary of Interests

I do not have any interests to disclose at this time.

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-19270

## Summary of Interests

| Company or Organization                                   |            |   |
|---|------------|---|
| Entity  | Type       | Interest Held By  |
| <a href="#">Discovery Health</a>                          | Employment | Self  |
| <i>Title:</i> Deputy General Manager - Data and Analytics |            | <i>Position Description:</i> Lead a data and analytics team focused on healthcare cost and quality optimisation |
| <i>Additional Information:</i>                            |            |   |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-19270

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-19270

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Effectiveness of BNT162b2 vaccine against Omicron Variant in South Africa
- 3. **Are you the corresponding author?**  
Yes.
  - a. **Please list the other authors' names here.**  
Shirley Collie Jared Champion Harry Moultrie Linda Gail Bekker

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-19270

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.